NEW YORK – Diagnostic firm Oncocyte made a surprising announcement this June that it was discontinuing efforts to bring its blood-based lung cancer detection assay, DetermaDx, to the clinic, after more than five years of development and having reached the final stages of clinical validation.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.